Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net loss	$ (27,692)	$ (18,581)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,469	1,476
Non-cash lease expense	254	215
Stock-based compensation expense	4,036	1,898
Change in fair value of stock warrants	652	(31)
Change in fair value of contingent consideration	1,633	(110)
Other non-cash reconciling items	(1)	(2)
Change in operating assets and liabilities:
Prepaid expenses, other current assets and other assets	(177)	337
Accounts payable	1,338	(930)
Accrued compensation	(177)	554
Accrued clinical trial site costs	15	(594)
Operating lease liabilities	(242)	(218)
Other liabilities	266	348
Net cash used in operating activities	(18,626)	(15,638)
Cash flows from investing activities:
Purchases of property and equipment		(7)
Net cash used in investing activities		(7)
Cash flows from financing activities:
Proceeds from sale of common stock and common stock warrants, net of issuance costs	17,074
Proceeds from sale of common stock and pre-funded warrants, net of costs		14,108
Proceeds from exercise of common stock warrants, net of costs	19,445
Proceeds received prior to for issuance of common stock and pre-funded warrants	19,932
Proceeds from stock option exercises	10
Tax withholding payments for net share-settled equity awards		(16)
Net cash provided by financing activities	56,461	14,092
Net increase (decrease) in cash and cash equivalents	37,835	1,553
Cash and cash equivalents, beginning of period	14,602	21,304
Cash and cash equivalents, end of period	52,437	$ 19,751
Supplemental disclosure of non-cash financing information
Operating lease right-of-use assets obtained in exchange for operating lease obligations	597
Unpaid financing costs included in accounts payable and accrued liabilities	$ 199